Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation

1. Age 18-65 years 2. Chronic Kidney Disease stage 5 receiving hemodialysis 3. Authorization (Consent) for Use/Disclosure of Data signed by the patient 4. Planned prescription of Zemplar treatment due to fair clinical need and irrespectively of the participation in the current program according to the local label within 2 weeks after screening into the program 5. Screening intact Parathyroid Hormone level (measured not earlier than 1 month before first dose of Zemplar) between 300 and 900 pg/mL

1. Contraindications to Zemplar as indicated in approved label, including but not limited to hypersensitivity, hypervitaminosis D (serum D3 level above 32 ng/mL), concomitant use of vitamin D or phosphates, lactation period, pregnancy 2. Any experimental drug within the period of 30 days before the inclusion into the program 3. Screening Ca x P \> 65 mg˄2/dL˄2 4. Screening normalized serum total calcium \> 10.2 mg/dL 5. Necessity for calcitonin maintenance oral or intravenous glucocorticoids, or other drugs that could have affected calcium or bone metabolism, other than females on stable estrogen and/or progestin therapy